These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 21782064)

  • 1. Molecular targeted approaches in mantle cell lymphoma.
    Weniger MA; Wiestner A
    Semin Hematol; 2011 Jul; 48(3):214-26. PubMed ID: 21782064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New molecular targets in mantle cell lymphoma.
    Parekh S; Weniger MA; Wiestner A
    Semin Cancer Biol; 2011 Nov; 21(5):335-46. PubMed ID: 21945517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current status of targeted therapies for mantle cell lymphoma.
    Chang JE; Kahl BS
    Drugs; 2011 Dec; 71(17):2307-26. PubMed ID: 22085387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.
    Dasmahapatra G; Patel H; Dent P; Fisher RI; Friedberg J; Grant S
    Br J Haematol; 2013 Apr; 161(1):43-56. PubMed ID: 23360303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.
    Müller A; Zang C; Chumduri C; Dörken B; Daniel PT; Scholz CW
    Int J Cancer; 2013 Oct; 133(8):1813-24. PubMed ID: 23580240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NF-κB signaling and its relevance to the treatment of mantle cell lymphoma.
    Balaji S; Ahmed M; Lorence E; Yan F; Nomie K; Wang M
    J Hematol Oncol; 2018 Jun; 11(1):83. PubMed ID: 29907126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mantle cell lymphoma in relapse: the role of emerging new drugs.
    Diefenbach CS; O'Connor OA
    Curr Opin Oncol; 2010 Sep; 22(5):419-23. PubMed ID: 20679769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel targeted therapeutics for mantle cell lymphoma--what's on the horizon?
    El Halabi L; Ghez D; Ribrag V
    Expert Rev Hematol; 2016 Mar; 9(3):271-81. PubMed ID: 26689790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.
    Li J; Wang X; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Pan Z; Ding N; Song Y; Zhu J
    Int J Cancer; 2018 Jan; 142(1):202-213. PubMed ID: 28905990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temsirolimus for the treatment of mantle cell lymphoma.
    Hess G
    Expert Rev Hematol; 2009 Dec; 2(6):631-40. PubMed ID: 21082954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel targeted therapies for mantle cell lymphoma.
    Alinari L; Christian B; Baiocchi RA
    Oncotarget; 2012 Feb; 3(2):203-11. PubMed ID: 22361516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma - where do they fit in?
    Rule S; Chen RW
    Expert Rev Hematol; 2018 Sep; 11(9):749-756. PubMed ID: 30052472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temsirolimus in mantle cell lymphoma and other non-Hodgkin lymphoma subtypes.
    Hess G; Smith SM; Berkenblit A; Coiffier B
    Semin Oncol; 2009 Dec; 36 Suppl 3():S37-45. PubMed ID: 19963099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma.
    Arkwright R; Pham TM; Zonder JA; Dou QP
    Expert Opin Drug Discov; 2017 Feb; 12(2):225-235. PubMed ID: 27917682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era.
    Pérez-Galán P; Dreyling M; Wiestner A
    Blood; 2011 Jan; 117(1):26-38. PubMed ID: 20940415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on the molecular pathogenesis and targeted approaches of mantle cell lymphoma: summary of the 12th annual conference of the European Mantle Cell Lymphoma Network.
    Dreyling M; Amador V; Callanan M; Jerkeman M; Le Gouill S; Pott C; Rule S; Zaja F;
    Leuk Lymphoma; 2015 Apr; 56(4):866-76. PubMed ID: 25015778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
    Kim A; Seong KM; Kang HJ; Park S; Lee SS
    Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
    Dawar R; Hernandez-Ilizaliturri F
    Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mantle cell lymphoma: the promise of new treatment options.
    Goy A; Kahl B
    Crit Rev Oncol Hematol; 2011 Oct; 80(1):69-86. PubMed ID: 21168343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Mantle Cell Lymphoma -  Cutting edge Dia-gnostics and Treatment Approaches].
    Klener P; Trněný M
    Klin Onkol; 2015; 28 Suppl 3():3S80-6. PubMed ID: 26489506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.